StrongIncrease
Bone mineral density (BMD)
Eldecalcitol → Bone mineral density (BMD)
Eldecalcitol → Bone mineral density (BMD)
Evidence profile
StrongIncreaseClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Eldecalcitol may reduce diabetes risk in pre-diabetics with low insulin
Key finding
Hazard ratio 0.87, 95% confidence interval 0.67 to 1.17; P=0.39
This study evaluated the effectiveness of eldecalcitol in preventing type 2 diabetes in adults with impaired glucose tolerance. It found no significant difference in diabetes incidence between eldecalcitol and placebo groups.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Eldecalcitol, Placebo
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
Incidence of type 2 diabetes
Comparator
Placebo group
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effectiveness of eldecalcitol in preventing type 2 diabetes in adults with impaired glucose tolerance. It found no significant difference in diabetes incidence between eldecalcitol and placebo groups.
Clinical relevance
Understanding whether eldecalcitol can prevent type 2 diabetes is crucial, especially for individuals with impaired glucose tolerance who are at higher risk. The findings suggest that while eldecalcitol may improve bone health, it may not be effective for diabetes prevention, highlighting the need for alternative strategies in managing diabetes risk.
Keep in mind
The study's follow-up duration may not capture long-term effects. Results may not be generalizable to populations outside the study sample. Effectiveness of eldecalcitol for diabetes prevention remains unclear.
Published in
Journal Reference
Publication details and source links for this paper.
Tetsuya K, Gen S, Shoichi M, et al. Eldecalcitol for the prevention of type 2 diabetes in adults with impaired glucose tolerance: a randomized controlled trial. The BMJ. 2022;377:e066222. doi:10.1136/bmj-2021-066222
Save this study and add notes to your research library.
Main Effects
Eldecalcitol group had a 12.5% incidence of type 2 diabetes compared to 14.2% in the placebo group (hazard ratio 0.87).
23.0% of eldecalcitol participants achieved regression to normoglycaemia versus 20.1% in the placebo group (hazard ratio 1.15).
Bone mineral density of lumbar spine and femoral neck significantly increased with eldecalcitol (P<0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Eldecalcitol and Bone mineral density (BMD), Regression to normoglycaemia, Serum osteocalcin, and 1 more.
This study contributes evidence to
Primary intervention
Eldecalcitol
Primary outcomes
- Bone mineral density (BMD)
- Regression to normoglycaemia
- Serum osteocalcin
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
4
Evidence pairs
3
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneNo Change
Regression to normoglycaemia
Eldecalcitol → Regression to normoglycaemia
Eldecalcitol → Regression to normoglycaemia
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
StrongIncrease
Serum osteocalcin
Eldecalcitol → Serum osteocalcin
Eldecalcitol → Serum osteocalcin
Evidence profile
StrongIncreaseClinical Outcomes
Unlock full evidence details
NoneNo Change
Type 2 diabetes incidence
Eldecalcitol → Type 2 diabetes incidence
Eldecalcitol → Type 2 diabetes incidence
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Eldecalcitol did not significantly reduce diabetes incidence (hazard ratio 0.87, p=0.39).
- Improved bone mineral density was observed with eldecalcitol (all P<0.001).
- Regression to normoglycaemia was slightly higher in the eldecalcitol group (23.0% vs. 20.1%).
Who this applies to
- Adults aged 18-75 with impaired glucose tolerance.
- Individuals at risk for developing type 2 diabetes.
Keep in Mind
- The study did not measure long-term diabetes outcomes beyond 2.9 years.
- The sample may not represent all demographics at risk for diabetes.
- Further research is needed to explore alternative diabetes prevention strategies.
Between the Lines
- The study's follow-up duration may not capture long-term effects.
- Results may not be generalizable to populations outside the study sample.
- Effectiveness of eldecalcitol for diabetes prevention remains unclear.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Eldecalcitol and Bone Mineral Density, Eldecalcitol and Serum osteocalcin.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Bone Mineral Density Evidence Hub
All studies measuring Bone Mineral Density
1 studies
outcome_hubMeasures Bone Mineral Density as a key outcome.
Eldecalcitol Evidence Hub
All studies on Eldecalcitol
1 studies
intervention_hubContributes to Eldecalcitol evidence base.
Serum osteocalcin Evidence Hub
All studies measuring Serum osteocalcin
1 studies
outcome_hubMeasures Serum osteocalcin as a key outcome.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Eldecalcitol and Bone mineral density (BMD)
Intervention: EldecalcitolOutcome: Bone mineral density (BMD)
1 results
All studies on Eldecalcitol and Serum osteocalcin
Intervention: EldecalcitolOutcome: Serum osteocalcin
1 results
All studies on Eldecalcitol
Intervention: Eldecalcitol
1 results
All studies measuring Bone mineral density (BMD)
Outcome: Bone mineral density (BMD)
1 results
All studies measuring Serum osteocalcin
Outcome: Serum osteocalcin
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Eldecalcitol improve bone mineral density (bmd)?
Emerging Evidence
Eldecalcitol appears to improve Bone mineral density (BMD).
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Bone mineral density (BMD)
EvidenceScore™ Emerging | EvidenceScore™ 55.7 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Eldecalcitol improve serum osteocalcin?
Emerging Evidence
Eldecalcitol appears to improve Serum osteocalcin.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Serum osteocalcin
EvidenceScore™ Emerging | EvidenceScore™ 55.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Eldecalcitol improve regression to normoglycaemia?
Limited Evidence
Current evidence does not show a clear benefit of Eldecalcitol for Regression to normoglycaemia.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Regression to normoglycaemia
EvidenceScore™ Limited | EvidenceScore™ 38.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Eldecalcitol improve type 2 diabetes incidence?
Limited Evidence
Current evidence does not show a clear benefit of Eldecalcitol for Type 2 diabetes incidence.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Type 2 diabetes incidence
EvidenceScore™ Limited | EvidenceScore™ 38.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Dapagliflozin shows no long-term harm to bone health in women with diabetesDaqing Diabetes Prevention Study IIEngagement in a prediabetes education programme is linked to lower type 2 diabetes riskIntensive lifestyle programme cuts type 2 diabetes risk by 57% in European prediabetes trialLiraglutide improves glycaemic control in adults with T2D
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.